login
Password reminder
Cardiovascular News
Contact the editor Visit Cardiovascular News Twitter feed Visit Cardiovascular News Facebook page
 

First study to evaluate alternative to warfarin for mechanical heart valve patients launched


Thursday, 21 Jun 2012 11:55



The American Heart Journal has published the design of the RE-ALIGN study, the first study to evaluate dabigatran etexilate (Pradaxa, Boehringer Ingelheim) as alternative to warfarin for use in patients with mechanical heart valves requiring anticoagulation therapy.


RE-ALIGN (Randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement) addresses current limitations experienced with warfarin and is designed to identify safe and effective dosing regimen of dabigatran for the prevention of valve thrombosis, stroke and systemic embolism in this patient population, prior to further investigation in a larger phase III study.The current approval of dabigatran does not cover the use in patients with mechanical heart valves.

Vitamin K antagonists, such as warfarin, are the current long-term standard for anticoagulation of patients with a cardiac valve replacement. However, there is only limited information available on the long-term risk of thrombotic and haemorrhagic complications associated with this therapy in patients with modern mechanical bileaflet valves. Additionally, in spite of frequent INR monitoring, patients treated with warfarin spend less that 65% of the time within the targeted therapeutic range (TTR), with TTR in the first three months following valve replacement surgery reported to be as low as 48.5%.


“It is vital that patients with mechanical heart valves are provided with anticoagulant therapies that are safe and effective over the long-term. The current treatment with vitamin K antagonists is associated with significant limitations, creating a need for novel options which have fewer interactions and do not require regular monitoring. We are proud to be the first company looking for an alternative option for these patients by investigating Pradaxa in the RE-ALIGN trial,” said Klaus Dugi, corporate senior vice president Medicine, Boehringer Ingelheim.


The RE-ALIGN study, a prospective, randomised, phase II study, evaluates dabigatran in patients with mechanical bileaflet heart valve during a follow-up period of 12 weeks.Based on the results, a sufficiently powered phase III study is planned to investigate efficacy outcomes for dabigatran in this patient population.


“Pradaxa has already been proven to be a safe and efficacious anticoagulant treatment for stroke prevention in patients with atrial fibrillation,” said Frans Van de Werf, Department of Cardiovascular Medicine, University Hospitals Leuven, Belgium. “However, the presence of a mechanical heart valve is a distinct clinical situation requiring different dosing. The aim of the RE-ALIGN study is to identify dosing regimens of Pradaxa that are expected to be safe and effective for the prevention of thromboembolic complications in patients with mechanical heart valves.”


The different dosing regimens that are under investigation for dabigatran in RE-ALIGN are 150mg bid, 220mg bid, and 300mg bid, with the starting dose determined by the individual patient’s creatinine clearance. The study includes patients with recent surgery for implantation of mechanical bileaflet heart valve who have not yet started oral anticoagulation, and patients who had surgery at least three months before randomisation and are currently taking an oral vitamin K antagonist. Patients are randomised to receive either dabigatran or warfarin. After the 12 week study period, patients are given the opportunity to opt-in to continue treatment with dabigatran within the RE-ALIGN extension trial, allowing investigators to collect long-term safety data.


To date, no investigation has been undertaken to determine the efficacy and safety of any novel oral anticoagulant including dabigatran in patients with mechanical heart valves. Until such data are available, the use of dabigatran for the prevention of thromboembolic complications in patients with mechanical heart valves is not recommended nor approved for clinical practice and is restricted to the setting of a randomised clinical trial only.




Add New Comment

Related Items


Most popular


Abbott to acquire St Jude Medical
Tuesday, 03 May 2016
Abbott is set to acquire St Jude Medical, expanding its portfolio to cover cardiovascular markets such as atrial fibrillation, structural heart and heart failure as well as neuromodulation. The ... Abbott to acquire St Jude Medical

European Union agrees new rules for approving medical devices and in vitro diagnostic medical devices
Tuesday, 31 May 2016
The Netherlands presidency of the European Council and representatives of the European Parliament have reached a political agreement on two draft regulations for medical devices. The new regulations ... European Union agrees new rules for approving medical devices and in vitro diagnostic medical devices

Young female acute coronary syndrome patients have significantly greater comorbidities than their male counterparts
Wednesday, 11 May 2016
A study indicates that women aged less than 55 years with acute coronary syndrome undergoing percutaneous coronary intervention (PCI) have significantly greater comorbidities and worse outcomes than ... Young female acute coronary syndrome patients have significantly greater comorbidities than their male counterparts

Features


Trials on newer generation drug-eluting stents in small coronary vessels needed
Monday, 27 Jun 2016
A network meta-analysis of early generation, drug-eluting stents, bare metal stents, drug-coated balloons, and balloon angioplasty indicate that sirolimus-eluting stents are associated with the most ... Trials on newer generation drug-eluting stents in small coronary vessels needed

Online medical information: A blessing or a curse?
Thursday, 23 Jun 2016
The internet age has enabled patients to access a plethora of medical information. However, a potential drawback is that some of this information is inaccurate or misleading—causing unnecessary ... Online medical information: A blessing or a curse?

Profiles


James Blankenship
Wednesday, 08 Jun 2016
James Blankenship is the 2015–2016 president of SCAI and has been involved with designing and ... James Blankenship

Alexandra Lansky
Monday, 07 Mar 2016
Alexandra Lansky (Director, Heart and Vascular Clinical Research Program, Yale University School of ... Alexandra Lansky

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions